Open Access<p>Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients</p>
Author(s) -
Arschang Valipour,
Michael Tamm,
J Kociánová,
Valentina Bayer,
Maria Sanzharovskaya,
Alexey Medvedchikov,
Monika Haaksma-Herczegh,
János Mucsi,
Zvi G. Fridlender,
Claudia Toma,
А. С. Белевский,
Bohumil Matula,
J Sorli
Publication year - 2019
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s204388
Subject(s) - medicine , copd , clinical endpoint , lama , muscarinic antagonist , physical therapy , fixed dose combination , tiotropium bromide , anesthesia , randomized controlled trial , antagonist , lung , lung function , receptor
Reduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β 2 -agonist olodaterol increases exercise capacity. This study assessed the effects of a fixed-dose combination (FDC) of tiotropium/olodaterol (delivered via Respimat ® ) on physical functioning in patients with stable COPD in a "real-world setting".